AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30735141 — intervention group
Group type: COMPARATOR
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 362
Study 30735255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute intravenous alcohol infusion
Number of subjects: 24
Study 30735342 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-time (days spent at home for the first 90 days after aSAH)
Number of subjects: 1076
Study 30735474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine adoption at no-cost
Number of subjects: 615
Study 30735474 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccine adoption with cost (25€ per person)
Number of subjects: 615
Study 30735593 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing early salpingectomy and delayed oophorectomy
Number of subjects: 0
Study 30736150 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 0
Study 30736150 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 30736445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat diet (Swank)
Number of subjects: 0
Study 30736445 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Paleolithic diet (WahlsElim)
Number of subjects: 0
Study 30736445 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30736779 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based questionnaire assessing PRMDs and risk factors
Number of subjects: 3000
Study 30736818 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP point-of-care test intervention
Number of subjects: 130
Study 30736848 — intervention group
Group type: EXPERIMENTAL
Intervention: BI1361849 (CV9202) combined with local radiation (4 × 5 Gy)
Number of subjects: 26
Study 30736848 — intervention group
Group type: EXPERIMENTAL
Intervention: BI1361849 (CV9202)
Number of subjects: 26
Study 30736848 — intervention group
Group type: EXPERIMENTAL
Intervention: BI1361849 (CV9202) with pemetrexed maintenance
Number of subjects: 26
Study 30736852 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogenic γδ T cell immunotherapy (8 infusions from August 2017 to February 2018)
Number of subjects: 1
Study 30736874 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP adherence in the first 3 months (usage of the device for at least 4 hours per night on 70% of nights)
Number of subjects: 42
Study 30736874 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP adherence after the first 3 months
Number of subjects: 42
Study 30736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of adherence at 3 months for adherence at 1 year
Number of subjects: 42
Study 30736874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity of using adherence at 3 months to predict adherence at 1 year
Number of subjects: 42
Study 30737049 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of Dietary Inflammatory Index (DII)
Number of subjects: 1948
Study 30737049 — intervention group
Group type: EXPERIMENTAL
Intervention: DII score
Number of subjects: 1948
Study 30737137 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management (ultrasound and clinical follow-up at intervals of 3 months, 6 months, and then every 12 months thereafter)
Number of subjects: 2587
Study 30737137 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 2587
Study 30737315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam (5-60 mg)
Number of subjects: 1426
Study 30737315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1426
Study 30737315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam 5 mg
Number of subjects: 1426
Study 30737315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam 7.5 mg
Number of subjects: 1426
Study 30737315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam 15 mg
Number of subjects: 1426
Study 30737315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meloxicam
Number of subjects: 1426
Study 30738245 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal life support during cardiopulmonary resuscitation (ECPR)
Number of subjects: 110
Study 30738245 — intervention group
Group type: COMPARATOR
Intervention: Continued cardiopulmonary resuscitation (CCPR)
Number of subjects: 110
Study 30738245 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR
Number of subjects: 110
Study 30738398 — intervention group
Group type: EXPERIMENTAL
Intervention: TiRobot-assisted group (RG)
Number of subjects: 234
Study 30738398 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-assisted group (FG)
Number of subjects: 234
Study 30738398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study 30738400 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the caudate nucleus body
Number of subjects: 6
Study 30738400 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation of the caudate head
Number of subjects: 6
Study 30738400 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity comparison between caudate body and head
Number of subjects: 6
Study 30738407 — intervention group
Group type: EXPERIMENTAL
Intervention: CoGNIT (Computerized General Neuropsychological INPH Test) administered preoperatively and at a postoperative follow-up 4 months after shunt surgery
Number of subjects: 41
Study 30738407 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly control volunteers
Number of subjects: 41
Study 30738658 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (adjusted to average rates at 25-26 weeks, 89.2%) for resuscitated infants born at 23 weeks
Number of subjects: 4858
Study 30738658 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation without antenatal corticosteroids for infants born at 23 weeks
Number of subjects: 4858
Study 30738658 — intervention group
Group type: COMPARATOR
Intervention: Discordant antenatal corticosteroid use and resuscitation for infants born at 22 weeks
Number of subjects: 4858
Study 30738658 — intervention group
Group type: COMPARATOR
Intervention: Discordant antenatal corticosteroid use and resuscitation for infants born at 23 weeks
Number of subjects: 4858
Study 30738658 — intervention group
Group type: COMPARATOR
Intervention: Discordant antenatal corticosteroid use and resuscitation for infants born at 24 weeks
Number of subjects: 4858
Study 30738658 — intervention group
Group type: COMPARATOR
Intervention: Resuscitation for infants born at 22 weeks
Number of subjects: 4858
Study 30738985 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS
Number of subjects: 37
Study 30738985 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP
Number of subjects: 37
Study 30738985 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCP grade 2
Number of subjects: 37
Study 30739055 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic impedance (TI) monitoring
Number of subjects: 497
Study 30739055 — intervention group
Group type: EXPERIMENTAL
Intervention: TI monitoring during intensified diuresis
Number of subjects: 497
Study 30739055 — intervention group
Group type: EXPERIMENTAL
Intervention: TI monitoring for recurrent decompensations
Number of subjects: 497
Study 30739258 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic model for overall survival (OS) in second-line treatment.
Number of subjects: 1076
Study 30739258 — intervention group
Group type: EXPERIMENTAL
Intervention: New independent prognostic factors identified: time from first to second-line treatment and tumor burden.
Number of subjects: 1076
Study 30739258 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk groups based on GRCC model.
Number of subjects: 1076
Study 30739366 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruzasvir 60 mg plus Uprifosbuvir 450 mg
Number of subjects: 160
Study 30739368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin (OBV/PTV/r ± DSV ± RBV)
Number of subjects: 3808
Study 30739387 — intervention group
Group type: EXPERIMENTAL
Intervention: C4M levels in females
Number of subjects: 0
Study 30739387 — intervention group
Group type: EXPERIMENTAL
Intervention: C4M levels in males
Number of subjects: 0
Study 30739387 — intervention group
Group type: EXPERIMENTAL
Intervention: C4M as a predictor
Number of subjects: 0
Study 30739387 — intervention group
Group type: EXPERIMENTAL
Intervention: C4M and PRO-C4 levels
Number of subjects: 0
Study 30739387 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-specific profiles of C4M
Number of subjects: 0
Study 30739576 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive perampanel oral suspension (≤0.18 mg/kg/d)
Number of subjects: 0
Study 30740545 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) treatments lasting 20-45 minutes twice weekly for 2-4 months during feeding therapy sessions by a trained occupational therapist (OT).
Number of subjects: 10
Study 30740662 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone)
Number of subjects: 0
Study 30740662 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab)
Number of subjects: 0
Study 30740662 — intervention group
Group type: EXPERIMENTAL
Intervention: End of treatment positron emission tomography scans
Number of subjects: 0
Study 30740662 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage immunochemotherapy and subsequent autologous stem cell transplantation
Number of subjects: 0
Study 30740662 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies targeting aberrant cellular signalling and immune evasion
Number of subjects: 0
Study 30740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 31
Study 30740673 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin and VAT adipocyte area
Number of subjects: 31
Study 30740673 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT adipocyte area
Number of subjects: 31
Study 30741382 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide extended-release (TA-ER) injection
Number of subjects: 208
Study 30741501 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest pressure pain thresholds (PPTs) in finger joints and remote locations
Number of subjects: 282
Study 30741501 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of temporal summation (TS)
Number of subjects: 282
Study 30741501 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds (PPTs) and presence of TS
Number of subjects: 282
Study 30741694 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30741695 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30741812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 300
Study 30741812 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone (400 mg once a day)
Number of subjects: 300
Study 30742211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (n=1414)
Number of subjects: 3010
Study 30742211 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n=1422)
Number of subjects: 3010
Study 30742211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3010
Study 30742211 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3010
Study 30742483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional mobilization in an orthosis
Number of subjects: 34
Study 30742559 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem-cell transplantation (HSCT) in first complete remission (CR1)
Number of subjects: 131
Study 30742559 — intervention group
Group type: COMPARATOR
Intervention: No HSCT
Number of subjects: 131
Study 30742559 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MRD of 0.01% or greater at the end of induction
Number of subjects: 131
Study 30742566 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib 25 mg orally twice daily in 28-day cycles until progression, unacceptable toxicity, or death
Number of subjects: 129
Study 30742566 — intervention group
Group type: EXPERIMENTAL
Intervention: Duvelisib 25 mg orally twice daily
Number of subjects: 129
Study 30742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and Art components
Number of subjects: 4681
Study 30742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous practice of diet, art, and biofield therapy
Number of subjects: 4681
Study 30742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of components practiced
Number of subjects: 4681
Study 30742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased frequency of components practiced
Number of subjects: 4681
Study 30742776 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofield therapy
Number of subjects: 4681
Study 30742809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution CT (HRCT) scanning indexes
Number of subjects: 70
Study 30742809 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly defined parameter AROIP
Number of subjects: 70
Study 30742833 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 36
Study 30742833 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 36
Study 30742833 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36
Study 30743197 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcephaly
Number of subjects: 132
Study 30743197 — intervention group
Group type: EXPERIMENTAL
Intervention: Major ultrasound abnormalities
Number of subjects: 132
Study 30743197 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of microcephaly and major ultrasound abnormalities
Number of subjects: 132
Study 30743197 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal neurological examination, no major ultrasound findings, normal head size
Number of subjects: 132
Study 30743197 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcephaly or major ultrasound abnormalities
Number of subjects: 132
Study 30743210 — intervention group
Group type: EXPERIMENTAL
Intervention: No-Touch vein harvesting technique
Number of subjects: 2000
Study 30743210 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 2000
Study 30744116 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walking test (6MWT)
Number of subjects: 42
Study 30744116 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO₂max)
Number of subjects: 42
Study 30744442 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (Tier 1: 800 mg loading dose followed by 200 mg BID for 7 days)
Number of subjects: 15
Study 30744442 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (Tier 2: 800 mg loading dose followed by 400 mg BID for 7 days)
Number of subjects: 15
Study 30744442 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (both tiers)
Number of subjects: 15
Study 30744568 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation based on clinical judgement
Number of subjects: 227
Study 30744568 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly contagious gastroenteritis (GE)
Number of subjects: 227
Study 30744568 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for Norovirus
Number of subjects: 227
Study 30744568 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for C. difficile infections
Number of subjects: 227
Study 30744587 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume analysis (BVA) using radiolabeled albumin to measure intravascular blood volume (BV) at baseline and after 1-3 months.
Number of subjects: 10
Study 30744587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had their prescribed estimated dry weight (EDW) changed after the initial BVA.
Number of subjects: 10
Study 30744587 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not have their prescribed EDW changed after the initial BVA.
Number of subjects: 10
Study 30744587 — intervention group
Group type: EXPERIMENTAL
Intervention: BVA measurements at the second measurement.
Number of subjects: 10
Study 30744587 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in weight.
Number of subjects: 10
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI (≥30)
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle index
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low muscle density
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low subcutaneous fat index
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low visceral fat index
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: High subcutaneous adipose tissue density
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: High visceral adipose tissue density
Number of subjects: 235
Study 30744591 — intervention group
Group type: EXPERIMENTAL
Intervention: High visceral fat density
Number of subjects: 235
Study 30744616 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bronchoscopy (performed during active bleeding/≤48 h after hemoptysis stopped)
Number of subjects: 486
Study 30744616 — intervention group
Group type: COMPARATOR
Intervention: Delayed examination
Number of subjects: 486
Study 30744616 — intervention group
Group type: EXPERIMENTAL
Intervention: Early bronchoscopy
Number of subjects: 486
Study 30744627 — intervention group
Group type: EXPERIMENTAL
Intervention: Quali-Palli-Patient questionnaire
Number of subjects: 214
Study 30744680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood analysis
Number of subjects: 1019
Study 30744680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord tissue analysis
Number of subjects: 1019
Study 30744680 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both tissues
Number of subjects: 1019
Study 30744681 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity (3 sessions of 60 min each per week, 2 supervised and 1 unsupervised)
Number of subjects: 280
Study 30744681 — intervention group
Group type: COMPARATOR
Intervention: Best practice usual care
Number of subjects: 280
Study 30745002 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 11308
Study 30745090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks (recommended phase 2 dose)
Number of subjects: 174
Study 30745090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks
Number of subjects: 174
Study 30745090 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin
Number of subjects: 174
Study 30745123 — intervention group
Group type: EXPERIMENTAL
Intervention: PSEN1 mutation (Ile416Thr)
Number of subjects: 93
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium everolimus-eluting stents (CoCr-EES)
Number of subjects: 17068
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-chromium EES (PtCr-EES)
Number of subjects: 17068
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (Re-ZES)
Number of subjects: 17068
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomatrix biolimus-eluting stents (Bi-BES)
Number of subjects: 17068
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori BES (No-BES)
Number of subjects: 17068
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: Xience Prime cobalt-chromium EES (Pr-CoCr-EES)
Number of subjects: 17068
Study 30745256 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation sirolimus-eluting stents (SES)
Number of subjects: 17068
Study 30745365 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous lymphocyte infusion combined with peri-autoSCT immunotherapy with recombinant MAGE-A3 and adjuvant
Number of subjects: 13
Study 30745399 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 22661
Study 30746241 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT-guided bronchoscopy
Number of subjects: 20
Study 30746241 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 20
Study 30746241 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose from CBCT
Number of subjects: 20
Study 30746241 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Number of subjects: 20
Study 30746344 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid (EPA) 2 g/day
Number of subjects: 36
Study 30746344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30746608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg BID (DE110)
Number of subjects: 4281
Study 30746608 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg BID (DE150)
Number of subjects: 4281
Study 30746608 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4281
Study 30746608 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 4281
Study 30746608 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelets
Number of subjects: 4281
Study 30746608 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from Warfarin to Dabigatran
Number of subjects: 4281
Study 30747243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous IL-2 (125,000 IU/kg/day, maximum 9-10 doses over 2 weeks)
Number of subjects: 12
Study 30747243 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative lymphodepleting chemotherapy, TIL, and low-dose IL-2
Number of subjects: 12
Study 30747243 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker assessment
Number of subjects: 12
Study 30747243 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL infusion product monitoring
Number of subjects: 12
Study 30747273 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs), hydroxyapatite (HA) granules, bone morphogenetic protein-2 (BMP-2), and mechanical stabilization
Number of subjects: 6